Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer

被引：0
|
作者：
Kohno, Norio
Hasegawa, Yoshie
Horiguchi, Jun
Ishikawa, Takashi
Miura, Daishu
Hayashi, Mitsuhiro
Takao, Shintaro
Kim, Seung Jin
Tanino, Hirokazu
Akazawa, Kohei
机构：
[1] Tokyo Med Univ Hosp, Dept Breast Oncol, Tokyo, Japan
[2] Hirosaki Municipal Hosp, Hirosaki, Aomori, Japan
[3] Gunma Univ, Sch Med, Maebashi, Gunma 371, Japan
[4] Yokohoma City Univ, Med Ctr, Dept Breast & Thyroid Surg, Yokohama, Kanagawa, Japan
[5] Toranomon Gen Hosp, Tokyo, Japan
[6] Tokyo Med Univ, Hachioji Med Ctr, Tokyo 1608402, Japan
[7] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[8] Oskaka Univ, Grad Sch Med, Osaka, Japan
[9] Naga Municipal Hosp, Wakayama, Japan
[10] Nigata Univ, Niigata, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1141
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    Hasegawa, Y.
    Kohno, N.
    Horiguchi, J.
    Miura, D.
    Ishikawa, T.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Tanino, H.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Yamagami, K.
    Akazawa, K.
    CANCER RESEARCH, 2012, 72
  • [2] A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer.
    Horiguchi, Jun
    Hasegawa, Yoshie
    Miura, Daishu
    Ishikawa, Takashi
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Tanino, Hirokazu
    Miyashita, Masaru
    Konishi, Muneharu
    Shigeoka, Yasushi
    Yamagami, Kazuhiko
    Akazawa, Kohei
    Kohno, Norio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Ishikawa, Takashi
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Yamagami, Kazuhiko
    Miyashita, Masaru
    Konishi, Muneharu
    Shigeoka, Yasushi
    Suzuki, Masato
    Taguchi, Tetsuya
    Kubota, Tomoyuki
    Akazawa, Kouhei
    Kohno, Norio
    PLOS ONE, 2015, 10 (12):
  • [4] Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)
    Miura, D.
    Hasegawa, Y.
    Horiguchi, J.
    Ishikawa, T.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Tanino, H.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Yamagami, K.
    Kaise, H.
    Akazawa, K.
    Kohno, N.
    CANCER RESEARCH, 2013, 73
  • [5] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
  • [6] Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
    Matsuda, Naoko
    Wang, Xiaoping
    Lim, Bora
    Krishnamurthy, Savitri
    Alvarez, Ricardo H.
    Willey, Jie S.
    Parker, Charla A.
    Song, Juhee
    Shen, Yu
    Hu, Jianhua
    Wu, Wenhui
    Li, Nan
    Babiera, Gildy V.
    Murray, James L.
    Arun, Banu K.
    Brewster, Abenaa M.
    Reuben, James M.
    Stauder, Michael C.
    Barnett, Chad M.
    Woodward, Wendy A.
    Le-Petross, H. T. Carisa
    Lucci, Anthony
    DeSnyder, Sarah M.
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JAMA ONCOLOGY, 2018, 4 (09) : 1207 - 1213
  • [7] Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
    Wei, Jinli
    Luo, Yulin
    Fu, Deyuan
    ONCOTARGETS AND THERAPY, 2018, 11 : 9049 - 9059
  • [8] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [9] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [10] Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
    Ishikawa, T.
    Akazawa, K.
    Hasegawa, Y.
    Tanino, H.
    Horiguchi, J.
    Miura, D.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Yamagami, K.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Suzuki, M.
    Taguchi, T.
    Kubota, T.
    Kohno, N.
    CANCER RESEARCH, 2017, 77
12345